Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Trial ID or NCT#
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
Contact us to find out if this trial is right for you.